10.20
-0.68(-6.25%)
Currency In USD
| Previous Close | 10.88 |
| Open | 10.78 |
| Day High | 10.83 |
| Day Low | 10.12 |
| 52-Week High | 46.8 |
| 52-Week Low | 3.76 |
| Volume | 48,314 |
| Average Volume | 77,812 |
| Market Cap | 62.74M |
| PE | -0.77 |
| EPS | -13.27 |
| Moving Average 50 Days | 9.08 |
| Moving Average 200 Days | 14.91 |
| Change | -0.68 |
If you invested $1000 in Aligos Therapeutics, Inc. (ALGS) since IPO date, it would be worth $27.47 as of September 15, 2025 at a share price of $10.2. Whereas If you bought $1000 worth of Aligos Therapeutics, Inc. (ALGS) shares 3 years ago, it would be worth $306.77 as of September 15, 2025 at a share price of $10.2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting
GlobeNewswire Inc.
Sep 03, 2025 8:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases,
Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 02, 2025 8:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases,
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs
GlobeNewswire Inc.
Aug 20, 2025 12:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, t